Profile data is unavailable for this security.
About the company
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
- Revenue in USD (TTM)33.54bn
- Net income in USD4.66bn
- Incorporated2014
- Employees95.00k
- LocationMedtronic PLCBuilding Two Parkmore Business Park WestDUBLIN H91 4K49IrelandIRL
- Phone+353 14381700
- Websitehttps://www.medtronic.com/
Mergers & acquisitions
| Acquired company | MDT:NYQ since announced | Transaction value |
|---|---|---|
| Fortimedix Surgical BV | 4.18% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cencora Inc | 310.23bn | 1.69bn | 57.24bn | 42.00k | 34.27 | 56.50 | 20.35 | 0.1845 | 8.62 | 8.62 | 1,574.00 | 5.23 | 4.59 | 16.40 | 12.70 | 7,386,481.00 | 2.53 | 1.12 | 10.78 | 4.84 | 3.29 | 3.24 | 0.55 | 0.2556 | 0.517 | 17.30 | 0.8694 | 62.15 | 12.12 | 10.36 | -13.53 | 13.02 | 9.45 | 4.98 |
| Medtronic PLC | 33.54bn | 4.66bn | 113.71bn | 95.00k | 24.54 | 2.37 | 15.06 | 3.39 | 3.62 | 3.62 | 26.01 | 37.46 | 0.3692 | 2.17 | 5.31 | 353,021.10 | 5.16 | 4.55 | 5.95 | 5.15 | 65.39 | 66.25 | 13.99 | 13.07 | 1.42 | 11.19 | 0.3714 | 84.20 | 3.62 | 3.01 | 26.82 | -0.2723 | 8.91 | 5.33 |
| Danaher Corp | 23.82bn | 3.77bn | 143.92bn | 61.00k | 38.99 | 2.83 | 23.51 | 6.04 | 5.16 | 5.16 | 32.62 | 71.06 | 0.2931 | 3.70 | 6.92 | 390,491.80 | 4.63 | 5.91 | 5.09 | 6.54 | 59.80 | 59.40 | 15.81 | 19.38 | 1.05 | 15.55 | 0.2447 | 14.68 | -0.0628 | 5.92 | -7.17 | 10.53 | 16.98 | 9.40 |
| Stryker Corp | 23.22bn | 2.86bn | 151.62bn | 53.00k | 53.54 | 7.24 | 38.67 | 6.53 | 7.41 | 7.41 | 60.17 | 54.78 | 0.5437 | 1.62 | 6.25 | 438,075.50 | 6.69 | 6.64 | 8.11 | 7.94 | 64.57 | 63.83 | 12.31 | 13.02 | 0.9985 | -- | 0.445 | 44.01 | 10.23 | 8.71 | -5.43 | 7.52 | 3.07 | 9.27 |
| Boston Scientific Corp | 17.55bn | 2.03bn | 155.02bn | 53.00k | 76.81 | 6.98 | 46.75 | 8.83 | 1.36 | 1.36 | 11.79 | 15.02 | 0.4571 | 2.02 | 7.03 | 331,188.70 | 5.27 | 3.08 | 6.10 | 3.57 | 68.73 | 68.51 | 11.54 | 7.78 | 0.8834 | 9.84 | 0.335 | 0.00 | 17.61 | 9.30 | 18.03 | 25.38 | 5.31 | -- |
| Thermo Fisher Scientific Inc | 42.90bn | 6.52bn | 159.10bn | 125.00k | 24.73 | 3.22 | 16.62 | 3.71 | 17.04 | 17.04 | 112.23 | 130.84 | 0.4374 | 4.86 | 4.47 | 343,184.00 | 6.73 | 7.68 | 7.81 | 9.02 | 41.34 | 44.24 | 15.38 | 16.64 | 1.38 | 24.80 | 0.4086 | 7.09 | 0.0513 | 10.92 | 5.67 | 11.33 | 8.62 | 15.48 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 118.81m | 9.26% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 68.93m | 5.37% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 60.04m | 4.68% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2025 | 41.57m | 3.24% |
| Geode Capital Management LLCas of 31 Mar 2025 | 27.92m | 2.18% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2025 | 27.53m | 2.15% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 14.57m | 1.14% |
| DWS Investment GmbHas of 31 Mar 2025 | 14.47m | 1.13% |
| BlackRock Investment Management (UK) Ltd.as of 31 Mar 2025 | 14.25m | 1.11% |
| Managed Account Advisors LLCas of 31 Mar 2025 | 13.94m | 1.09% |
